The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Issue 1 (19th June 2015)

• Record Type: Journal Article
• Authors: von Delft, Annette; Humphreys, Isla S; Brown, Anthony; Pfafferott, Katja; Lucas, Michaela; Klenerman, Paul; Lauer, Georg M; Cox, Andrea L; Gaudieri, Silvana; Barnes, Eleanor
• Is Part Of: Gut. Volume 65:Issue 1(2016)
• Page Start: 112
• Page End: 123
• Publication Date: 2015-06-19
• Subjects: HCV -- GENOTYPE -- CELLULAR IMMUNITY; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-308724
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Developing a vaccine that is cross-reactive between HCV genotypes requires data on T cell antigenic targets that extends beyond genotype-1. We characterised T cell immune responses against HCV genotype-3, the most common infecting genotype in the UK and Asia, and assessed within genotype and between genotype cross-reactivity. Design: T cell targets were identified in 140 subjects with either acute, chronic or spontaneously resolved HCV genotype-3 infection using (1) overlapping peptides and (2) putative human leucocyte antigens (HLA)-class-I wild type and variant epitopes through the prior assessment of polymorphic HCV genomic sites associated with host HLA, in IFNγ-ELISpot assays. CD4+/CD8+ T cell subsets were defined and viral variability at T cell targets was determined through population analysis and viral sequencing. T cell cross-reactivity between genotype-1 and genotype-3 variants was assessed. Results: In resolved genotype-3 infection, T cells preferentially targeted non-structural proteins at a high magnitude, whereas in chronic disease T cells were absent or skewed to target structural proteins. Additional responses to wild type but not variant HLA predicted peptides were defined. Major sequence viral variability was observed within genotype-3 and between genotypes 1 and 3 HCV at T cell targets in resolved infection and at dominant epitopes, with limited T cell cross-reactivity between viral variants. Overall 41 CD4/CD8+ genotype-3 T cell targets were identified with minimal overlap with those described for HCV genotype-1. Conclusions: HCV T cell specificity is distinct between genotypes with limited T cell cross-reactivity in resolved and chronic disease. Therefore, viral regions targeted in natural HCV infection may not serve as attractive targets for a vaccine that aims to protect against multiple HCV genotypes.